Thursday 31 August 2017

Phosphodiesterase Enzyme Inhibitors Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2024

Phosphodiesterase are a diverse family of enzymes (11 isoenzymes) that play a key role in regulating intracellular levels of secondary messengers - cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate. These enzymes identified to be pharmacologically active in the 1950s, hydrolyses cyclic nucleotides to treat various diseases such as cardiovascular, respiratory and erectile dysfunction. Distinct distribution of all the types of isoenzymes has provided possibilities for selective target therapies.

Request Sample Copy of the Business Report: https://www.coherentmarketinsights.com/insight/request-sample/172

The global phosphodiesterase enzyme inhibitors market can be better analyzed by classifying it into two classes as selective phosphodiesterase enzyme inhibitors and non-selective phosphodiesterase enzyme inhibitors. Theophylline and papaverineare the two most commonly used non-selective phosphodiesterase enzyme inhibitors for treating a range of diseases (bronchodilation, cardiac disorder, etc.). Advent of selective phosphodiesterase enzyme inhibitors has made a great impact in the medical treatment sector. Increasing understanding of the individual PDE isoforms has and will result in the emergence of better therapeutic drugs. Viagra (Sildenafil) is the best example to substantiate the success and impact of PDE inhibitors.

The global phosphodiesterase enzyme inhibitors market is majorly driven by PDE-5 inhibitors realizing the success of blockbuster drugs in these segment.

Increasing product developments to further improvise the phosphodiesterase enzyme inhibitors market outlook

The global phosphodiesterase enzyme inhibitors market has recently gained traction on account of the blockbuster PDE 5 inhibitor brands, Viagra and Cialis. This has also encouraged pharmaceutical companies to research on other PDE inhibitor class. In addition, research on extended use of approved PDE inhibitors is anticipated to benefit the drug in long term and contribute to the increasing revenues of PDE inhibitors market.
  • Researchers from the John Hopkin University reviewed the trials of PDE-5 inhibitors in pediatric patients with pulmonary hypertension. The researchers concluded that PDE-5 inhibitors can be safely prescribed to infants, neonates and children with primary and secondary pulmonary hypertension (2017).
  • Besides, PDE-5 inhibitor sildenafil accidently developed for treating angina, was also found to be effective in erectile dysfunction and now is observed to benefit heart attack patients. Researchers at Karolinska Institutet, Sweden reported in March 2017 that PDE-5 inhibitors prescribed for erectile dysfunction can lower the risk of death of hospitalization for heart failure in men who have had one heart attack in their lifetime.
  • Pfizer, Inc. received FDA approval for its PDE-4 inhibitor Crisaborole (Eucris) in December 2016 for the treatment of mild to moderate atopic dermatitis. Eucrisa the first non-steroidal topical monotherapy for skin disorder.
Browse Research Report At: https://www.coherentmarketinsights.com/ongoing-insight/phosphodiesterase-enzyme-inhibitors-market-172

Many such product developments would be augmenting the global PDE inhibitors market growth in near future.

New products are primarily targeted in develop economies like North America, Europe and Japan. However, product approval in emerging nations such as India, China, Brazil, Russia, Argentina, and Indonesia would potentially favorable for the market players. Increasing healthcare expenditure and large target population base would support the growth of PDE inhibitors market in these nations. However, market players need to be cautious about uncertain regulatory conditions favoring the economic status and healthcare need of the large patient population.

Some of the key players operating in the global phosphodiesterase enzyme inhibitors market include Pfizer, Inc., AstraZeneca plc, Bayer AG, Eli Lilly & Company, Celgene Corporation, Mist Pharmaceuticals.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Global Blood Processing Devices and Consumables Market Size to surpass US$ 49.3 Billion by 2024

The Global Blood Processing Devices and Consumables Market was valued at US$ 27.8 billion in 2015, according to a new report by published by Coherent Market Insights. Increasing geriatric population and rising emphasis of leading companies’ on long-term partnerships with end users is expected to boost demand for blood processing devices and consumables over the forecast period (2016–2024).

Request Sample Copy of the Business Report: https://www.coherentmarketinsights.com/insight/request-sample/83

Blood processing devices and consumables market size has grown manifold over the last decade. Much of its growth was attributed to government initiatives in setting up of blood screening center, especially in developing countries. The trend is especially prevalent in China, India, and Russia, with rampant increase in number of blood centers in these countries in the recent past. As a result of this, lucrative growth opportunities have emerged for industry players to expand their business reach across developing regions and enhance ROI over the forecast period.

There has been an increase in incidence rate of infectious diseases and chronic disorders such as cancer, especially among the geriatric population. According to the World Health Organization (WHO), in 2015, over 150 million people suffered from chronic hepatitis C virus, of which 700 thousand die each year owing to lack of suitable healthcare infrastructure and diagnosis centers. Technological advancements in the healthcare industry is expected to bridge the gap between patient’s expectation and healthcare delivery system. While the market for blood processing devices and consumables is highly saturated in developed regions, the developing regions, especially Asia Pacific is largely untapped and offers lucrative growth opportunities for market players.

Key takeaways of the market
  • Government has a critical role in creating national platforms for blood screening and blood bank centers. Increasing geriatric population along with rise in incidence rate of blood-related disorders is expected to create lucrative market opportunities for industry players
  • Cell processors device segment is expected to dominate the global blood processing devices market (in terms of revenue) throughout the forecast period. While, blood bags device segment is expected to lead the consumables market throughout the forecast period.
  • Asia Pacific dominated the global blood processing devices and consumables market, with a revenue share of around 17% of the total market in 2015. Growth of the regional market is mainly propelled by increasing demand from China, which accounted for 39% revenue share of the market in the region. The blood processing devices and consumables market in India is expected to expand at the highest CAGR in Asia Pacific during the forecast period.
To know the latest trends and insights prevalent in this market, click the link below: https://www.coherentmarketinsights.com/market-insight/blood-processing-devices-and-consumables-market-83
  • North America and Europe are highly matured market. Leading players such as Abbott Laboratories, Roche Holdings AG, and Terumo Corporation are emphasizing on establishing a direct distribution channel to retain their dominance in these regional markets. Setting up of cord blood bank center in these region is expected to create substantial market opportunity for industry players. Over 23 million blood components are transfused each year in North America.
  • There are over 13 thousand blood bank centers worldwide. The number is especially high in low to middle income countries, particularly India, Indonesia and Vietnam. Establishment of blood bank centers is expected to boost overall demand for blood bank refrigerators worldwide. The blood bank market is highly consolidated, with leading players accounting for around 80% of the global market. New entrants are expected to provide bank refrigerators during the forecast period.
  • While the overall blood processing device segment is consolidated, it is highly fragmented in consumables segment with large presence of regional players, especially in China and India.
About CMI

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Wednesday 30 August 2017

Light blue tube Phlebotomy Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2024

The process of drawing blood from veins is known as phlebotomy. The procedure, also known as venipuncture, is primarily performed by specialists called phlebotomists. Medical laboratory scientists, doctors, and nurses often perform phlebotomy process as well. Phlebotomy is carried out for a range of reasons such as blood donations, medical testing, and research.  Light blue top tubes are used for performing coagulation tests. Blood clotting or coagulation is the method by which blood changes its form. It forms a lump known as clot. This process leads to hemostasis, and prevent the blood loss from the body. The course of action of coagulation includes activation, bonding, and accumulation of platelets in addition to deposition and development of fibrin. Disorder related to clotting can result in thrombosis or hemorrhage. Phlebotomy tubes with light blue stoppers primarily contain two additives: sodium citrate (3.2% or 3.8%) and Citrate, theophylline, adenosine, dipyridamole) or CTAD. The citrate acts as an anticoagulant. It binds the calcium present in the blood that is required for clotting. As the additive gives a whole blood sample that is plasma and red blood cells, the light blue phlebotomy tubes have buffered tri-sodium citrate solution as well.

Request Sample Copy of the Business Report: https://www.coherentmarketinsights.com/insight/request-sample/143

Various tests are performed using the light blue phlebotomy tube. Some of them are Partial Thromboplastin Time (PTT), Fibrin degradation products (FDP), Thrombin Time (TT), Prothrombin Time (PT), Fibrinogen, and D-dimer. The global light blue tube phlebotomy market is expected to swell at a considerable rate in the near future. Rise in health awareness has resulted in the increase in blood diagnostic tests; particularly coagulation tests owing to mounting incidences of low platelet count, increased prevalence of liver diseases, as well as growth in number of surgeries are factors that will be responsible for the growth of light blue tube phlebotomy market.

Light Blue Tube Phlebotomy Market Taxonomy

On the basis of type of end user the global light blue tube phlebotomy market is classified into:
  • Hospitals
  • Diagnostic Centers
  • Medical Clinics
  • Others
An important factor for using light blue top tubes is the amount of blood extracted in the tubes. The tubes should be filled to the brim for obtaining accurate results. The blood should continue to flow from the patient’s body into the tube until the tube is full and the blood flow ceases. If the blood is extracted through a syringe, the optimum level (as marked in most of the light blue top tubes) should be maintained. This factor is important because light blue top tubes are used for coagulation tests which require 9:1 blood to anticoagulant ratio.

Asia Pacific to be growth engine for global light blue tube phlebotomy market

Increasing incidence of blood related diseases is projected to create a highly conducive environment for growth of the global light blue tube phlebotomy market. According to Center for Disease Control and Prevention, almost 1 to 2 people could be affected by DVT/PE. Pulmonary embolism (PE) typically occurs when a blood clot known as a deep vein thrombosis (DVT), habitually in the leg, moves to the lungs and form a lump, thereby blocking a blood vessel. It results into to low oxygen levels in the blood. It can harm the lung and may cause heart failure as well. Therefore, a blood coagulation test is usually suggested to patients with a history of such diseases. In South Asia, particularly in India, the blood fibrinogen level is usually high, owing to high prevalence of CHD or coronary heart diseases and elevated levels of glycoprotein IIb/IIIa which work as a receiver for fibrinogen. Moreover, according to a report by Journal of Thrombosis and Hemostatis, there is a growing emphasis upon the requirement of a controlled and randomized evaluation with clinical result measurement to ascertain that thromboprophylaxis (avoidance of thromboembolic disease or impediment of blood vessels by blood clot) is crucial in joint surgery in Asia. As blood coagulation tests are generally recommended before and after a surgery, escalation in the number of surgeries around the world is expected fuel the light blue tube phlebotomy market during the forecast period.

Browse Research Report At: https://www.coherentmarketinsights.com/ongoing-insight/light-blue-tube-phlebotomy-market-143

Key players in the global light blue tube phlebotomy market

Some of the major competitors operating in the global light blue tube phlebotomy market are Greiner BioOne, Medical Expo, CML Biotech Pvt. Ltd., Ajosha BioTeklik Pvt. Ltd., New MicroMed International Pvt. Ltd., FL Medical, Gosselin, and Advacare Pharma.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Tuesday 29 August 2017

Anti-Suicide Drugs Market, By Chemistry Type, and Geography - Insights, Opportunity Analysis, and Industry Forecast till 2024

Suicidal thoughts can be aroused due to various underlying factors such as financial burden, social issues or drug side effects. Treatment for suicidal thoughts includes psychotherapy, medications, addiction treatment, and family support. Anti-depressants and anti-psychotics are the most widely used medications for treating suicidal tendencies. According to the World Health Organization (WHO), over 800,000 people die due to suicide annually. Development of an effective anti-suicidal drug could be a major breakthrough in reducing the death toll. Currently, non-profit organizations such as Stop Suicide, Stop Youth Suicide, and American Foundation for Suicide Prevention are providing moral and social support to people with reported suicidal thoughts. This however, is ineffective until the organization is alerted of the person at risk for suicide.

Request Sample Copy of the Business Report: https://www.coherentmarketinsights.com/insight/request-sample/10

Market Dynamics

Off-label use of these drugs for suicidal ideation has been a practice for years, as there are no approved anti-suicide specific drug yet. However, the dynamics is expected to change in the following few years with the launch of first oral therapeutic drug for acute suicidal ideation. This would disrupt the use of antidepressants and anti-psychotic drugs for the treatment of suicidal tendencies. Suicidal incidences are high in low and middle income countries according to the WHO 2016 statistics. Although the incidence in Asia, East Africa, and Eastern European region is high, these regions lag in terms of availability of affordable medications and healthcare facilities. Therefore developed economies of North America and Western Europe are key target regions for manufacturers in the near future. Rampant economic growth and projected strengthening of the healthcare infrastructure in emerging economies in towards the first half of the following decade is projected to shift the focus of these companies towards highly populous regions of India and China in the long run.

Market Taxonomy

This report segments the global anti-suicide drugs market on the basis of chemistry type, and geography. On the basis of chemistry type, the market is categorized into anti-depressants and anti-anxiety drugs, anti-psychotic drugs, NMDA antagonist and antibiotic analogs. For comprehensive understanding of market dynamics, the global anti-suicide devices market is analyzed across key geographical regions namely North America, Europe, Asia Pacific, Latin America, Africa, and Middle East. Each of these regions is analyzed on basis of market findings across major countries in these regions for a macro-level understanding of the market.

To know the latest trends and insights prevalent in the anti-suicide drugs market, click the link below: https://www.coherentmarketinsights.com/market-insight/anti-suicide-drugs-market-10

Key features of the study:
  • This report provides in-depth analysis of the anti-suicide drugs and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR (%)) for the forecast period: 2016 – 2024, considering 2015 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
  • It profiles leading players in the global anti-suicide drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies and future plans
  • Key companies covered as a part of this study include Pfizer, Inc., AstraZeneca plc, Eli Lilly and Company, Allergan plc, GlaxoSmithKline plc, Merck & Co., Inc., Lundbeck A/S, NeuroRx, Inc., and Johnson & Johnson
  • Insights from this report would allow marketers and the management of companies to make informed decision with respect to their future product launch, competitive scenario, geographic expansion, and marketing tactics
  • The global anti-suicide devices market report caters to various stakeholders in this industry, including investors, drug manufacturers, distributors and suppliers, research and consulting firms, new entrants, and financial analysts
  • Various strategy matrices used in analyzing the anti-suicide drugs market would provide stakeholders vital inputs to make strategic decisions accordingly
About CMI

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Global Geriatric Care Services Market, By Service Type, and By Geography - Trends, Analysis and Forecast till 2024

Geriatric Care Services – Ageless Care

Aging increases the risk of chronic diseases such as diabetes, cardiac disorders, arthritis, and respiratory disorders that require continuous monitoring. Also, aging decreases bone density that makes it a challenge for the geriatric population to continuously manage their medical needs and perform their daily activities. Hence, the need for geriatric care services arises, which to a great extent eases the life of the elderly population. Increasing need for continuous health assistance by the elderly population is driving demand for continuing care.

The global geriatric care services market was valued at US$ 599.6 billion in 2015 and is expected to expand at a CAGR of 4.2% during the forecast period (2016 – 2024).

Request Sample Copy of the Business Report: https://www.coherentmarketinsights.com/insight/request-sample/88

Growing elderly population base driving the growth of geriatric care services market

Population aged 65 years and above is expected to grow more than 60% during the 2015-2030 (U.S. Census Bureau, 2015). The study estimates that the highest growth would be in Asia and Latin America. Africa on the other hand is the youngest region as of 2015 and is expected to remain so in the near future. Therefore, growth of elderly care in respective regions is estimated to follow a similar trend. However, affordability is one factor that would have negative impact on the growth of geriatric care services market in emerging economies such as India, Brazil, and China. Therefore, service providers need to offer cost-effective products in order to attract the relatively cost-sensitive customers in these countries. 

Increasing range of services by geriatric care centers to improve the geriatric care services market outlook

Geriatric care centers has evolved from being mere psychological support to nursing care and supervision. Geriatric care centers have well-trained specialists for different geriatric care needs. Services include health planning, problem-solving, health assessment and monitoring, home-care services, and personal care assistance. Furthermore, the providers of geriatric care services help customers to choose the most appropriate insurance policies as per their individual needs. The geriatric care managers also offer counseling and support, crisis intervention, decisions regarding appropriate housing options, money management, and assistance with moving an elderly to or from different types of housing. LivHome Technology+, by LivHome, Inc., addresses the safety issues, enables social engagement, and medication support. The company has LivHome Connect that includes 24 hour Active Remote Care (ARC) from in-house licensed nurses to the patients in need.

Browse Research Report At: https://www.coherentmarketinsights.com/market-insight/geriatric-care-services-market-88

Growing demand for continuing care in the global geriatric care services market

Geriatric care centers provide services include home healthcare, assisted living facilities, adult day care services, continuing care recruitment, and skilled nursing facilities. Skilled nursing facilities and home healthcare are the major revenue contributors for providers, owing to involvement of more time and workforce in these service types. However, demand for continuing care is increasing rapidly. Elderly population is highly prone to injuries, and therefore require continual care. Also, increasing women labor workforce participation has led to increase in demand for continuing care. The continuing care service type segment in the global geriatric care services market is projected to develop at a CAGR of 4.6% during the forecast period (2016-2024).

About CMI

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Cell Culture Market, By Product Type, Application, End User, and Geography - Trends, Analysis and Forecast till 2024

Cell Culture – Increased Production of Seasonal Influenza Vaccines

Cell culture is fast emerging as an important tool for diagnosing and clinically treating various disease such as cancer and Alzheimer’s. Companies are focusing on diversifying their cell depository and enhancing their expertise by laying major emphasis on recruitment of highly trained professionals in order to gain a competitive edge in the market. The European Collection of Authenticated Cell Cultures (ECACC) is serving the patent depository for Europe for carrying out research by acting as international depository authority. According to VF Bioscience SAS, cell culture technique is also gaining popularity in the field of food and beverages, a trend that is estimated to gain significant traction in 2017. Furthermore, cell culture are also gaining preference as an important ingredient in production of high quality plant actives. 

Request Sample Copy of the Business Report: https://www.coherentmarketinsights.com/insight/request-sample/116

Cell culture process can include various complications such as obtaining fully traceable botanical extracts and raw material supply. Furthermore, increasing focus on ensuring regulatory compliance related to environmental sustainability can hamper efficacy of the product. To overcome these complications in 2017, in place of using wild or field-grown plants, researchers at ABResearch srl utilized the callus cultures and cell suspension cultures for better results. According to News Medical Life-sciences, in 2017, researchers are inclined towards developing culture model that can be used in early treatment of age-related macular degeneration (AMD). AMD is the third major cause for total vision loss and also more prevalent in elderly people.

The global cell culture market was valued at US$ 12,251.3 million in 2015 and is expected to witness a robust CAGR of 7.1% during the forecast period (2016 – 2024).

High Investment in research and development by biotechnological companies

Players in the global cell culture market are making major investments in R&D to introduce advanced products used in the cell culture process owing to rise in number of application and better return on investment. Furthermore, companies are inclined towards novel product development. For instance, Biovest International, in 2009, has developed a product named AutovaxID-C, which is expected to reshape the biologic production made in the industry. The product favors the automated cell growth by replacing conventional cell growth chambers that use to acquire a large space in the laboratory. Various other factors such as increasing prevalence of chronic diseases, high importance of tissue or organ replacement with cell culture process, and increasing demand for antibody production are in turn projected to fuel cell culture market growth. Also, rise in prevalence of age-related macular degeneration is expected to underpin the cell culture market growth. Eye conditions such as diabetic retinopathy in tune with rise in number of diabetic patients globally in turn creates a conducive environment for growth of the cell culture market. AMD ranks third with a prevalence of around 8.7% globally in 2015, according to W.H.O.

To know the latest trends and insights prevalent in the Cell Culture Market click the link below: https://www.coherentmarketinsights.com/market-insight/cell-culture-market-116

 Major Player’s acquisitions are expected to fuel product diversification

An advanced and schematic integration of major players, followed by various acquisitions in cell culture market is fueling the frequency of product introduction in biotechnology and molecular biology field. Also, Advancements in mammalian cell culture techniques under recombinant protein production is propelling the cell culture market to new heights. In 2013, according to MDPI AG., Journal of Pharmaceutical, between 2006 and 2011, around 15 recombinant protein therapeutics were approved by U.S. FDA. Rise in number of biologics have spurred demand for biosimilars, which in turn is expected to fuel growth of the market for cell culture in the near future. In recent times, the global cell culture market has witnessed a high level of strategic mergers and acquisitions leading to development and advancement of new cell culture products. For instance:
  • In 2014, a Japan based stem cell company ReproCELL acquired Reinnervate Limited – a U.K based 3D Cell Culture Company along with a U.S. based human tissue supplier Bioserve, this is expected to help the company in the field of drug toxicity testing, neuroscience and cancer research by producing next-generation tools
  • In 2013, Bio-Rad Laboratories, Inc. – manufacturer of life science research and clinical diagnostic products purchased all the assets of a division of MorphoSys AG named AbD Serotec by paying US$ 71.3 million in cash, this is expected to favor the company’s antibody manufacturing power in terms of kits and accessories
  • In 2013, Evotec AG acquired Cell Culture Service GmbH – a Hamburg based company – this is expected to strengthen the company’s cell-based screening and reagent platform
Increasing number of research collaborations is expected to improve the time-to-market of highly effective and advanced products.

About CMI

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Monday 28 August 2017

Gastritis Treatment Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2024

Gastritis is the irritation, or inflammation, or erosion of the stomach lining. Gastritis may be acute or chronic. The disease may show some symptoms or the symptoms may be dormant. Usually, the symptoms include upper abdominal pain, nausea, and vomiting. Gastritis may lead to stomach tumors, bleeding, and stomach ulcers. Gastritis is usually caused by the bacteria helicobacter pylori or by the use of nonsteroidal anti-inflammatory drugs or NSAIDs. Other possible causes include smoking, cocaine, alcohol, and autoimmune diseases, among others. Treatment of gastritis includes H2 blockers, antacids, or proton pump inhibitors. In an acute gastritis attack, consumption of viscous lidocaine may be of assistance. If H. pylori are present, it may be cured with a combination drug therapy of antibiotics such as clarithromycin and amoxicillin. Gastritis can be cured by proper treatment; hence the demand of gastritis treatment is poised to rise in the foreseeable future.

Request Sample Copy of the Business Report: https://www.coherentmarketinsights.com/insight/request-sample/148

Chronic gastritis is one of the major diseases that affect a significant population of the globe and its prevalence is rising, according to a research report published in National Center for Biotechnology Information. It is estimated that nearly half the population of the world suffers from infection by helicobacter pylori, one of the main agent causing gastritis. There has been a growing concern about the prevalence of the disease around the world. As the disease is a curable disease, demand for its treatment is projected to increase at a steady pace. Technological advancements have brought about a sea change in the treatment of gastritis. According to a report by National Center for Biotechnology Information, patients with atropic gastritis (mucous glad metalapsia waste away) have higher chances of cancer, when compared to other forms of gastritis.

Gastritis Treatment Market Taxonomy

On the basis of drug class, the global gastritis treatment market is classified into:
  • Acid blocking medicines
  • Antibiotics
  • Antacids
  • Acid reducing medicines
  • Others
On the basis of end user, the global gastritis treatment market is classified into:
  • Government
  • Hospitals
  • Medical Practitioners
  • Others
Gastritis has been broadly categorized into three segments – acute gastritis (caused by NSAIDs and high alcohol consumption), chronic gastritis (variety of complication in the gastric tissues), and erosion of metalapsia or atrophic gastritis. Chronic gastritis is the most prevalent form of gastritis. Hence, the treatment of chronic gastritis will be the most promising market opportunity in the coming years.

Increasing prevalence of chronic gastritis, especially in the geriatric population offers promising growth for gastritis treatment market

There has been an increasing prevalence of gastritis, especially in the geriatric people around the globe. According to a report by National Center for Biotechnology Information, there were about 90 million new cases of gastritis in 2013. Gastritis and deodenitis (inflammation of the duodenum) caused about 60,000 deaths in 2013. As life expectancy has been increasing, the geriatric population of the globe is also on the rise. According to the same report, the prevalence of gastritis increase with age. Therefore, the demand for gastritis treatment will increase at a steady rate over the forecast period.

Browse Research Report At: https://www.coherentmarketinsights.com/ongoing-insight/gastritis-treatment-market-148

North America accounts for the maximum share of the market in the present scenario. Increasing prevalence of gastritis due to high alcohol consumption and unhealthy lifestyle and food habits are some of the reasons for the region’s dominance. However, Asia Pacific is expected to offer a lucrative market for the growth of the gastritis treatment market. The incidences of H pylori infection are high in Asia Pacific and other developing countries. Additionally, the prevalence of gastric adenocarcinomas and multifocal atrophic gastritis is high in these regions. Increase in geriatric population, better awareness about healthcare, and increased health care spending are some of the reasons that will fuel the growth of the gastritis treatment market in this region. Moreover, high occurrence of viral diseases, and autoimmune diseases, and lack of awareness about contagious diseases will propel the growth of the market.

The gastritis treatment market is highly fragmented in nature. Many companies are investing heavily in their research and development activities to come up with different treatments of the disease. Companies operating in the gastritis treatment market in the current scenario are Otsuka Indonesia PT, AstraZeneca PLC, Zydus Cadila Healthcare Limited, Novartis AG, and others.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Ubiquitin Enzymes Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2024

Ubiquitin enzymes, is also termed by E2 enzyme and seldom as known ubiquitin-carrier enzymes. This helps to achieve the second successive step in the ubiquitination process that aims at a protein to cut into various segments through the proteasome. The ubiquitination process firmly attaches ubiquitin, which is a short protein consisting of 76 amino acids, to a lysine deposit on the essential protein to be targeted. Once a protein gets attached with any of the ubiquitin moiety, excess rounds of ubiquitination form a polyubiquitin chain that is approved by the proteasome's 19S regulatory element.

Request Sample Copy of the Business Report: https://www.coherentmarketinsights.com/insight/request-sample/187

Ubiquitin Enzyme will not only profit big pharma companies but also small to mid-sized players and academic institutions.

Globally, there are numerous studies and research groups trying to explain the unseen potential of extremely difficult regulatory structure in order to progress the viable drug compound. Many literatures studies in a short span of 1 year, nearly 1500 journals related to ubiquitin enzymes are being published since 2015. A number of procedural advances in ubiquitin enzyme had led to the enhancement and development of varied technological platforms, research based assessment, tool essentials, chemicals and pioneer compounds to help the different drug discovery programs in different academic and industry researchers. In fact, the current conclusive trend-lines from different literature studies explains that not only big pharma giants but also small scale to mid-sized players and academic institutions.

There are various strategic partnerships evolved and had linked various stakeholders to advance research and development processes in Ubiquitin Enzymes Market. The growing field of research has gained the attention of various venture capital firms and investors. The emerging market, mainly focus on cancer indication, is likely to flourish in the long term and observer the rise of several successful drugs.

Cancer under application segment to dominate the Ubiquitin Enzymes Market over the forecast period

The global ubiquitin enzymes market is segmented on the basis of product type, application and geography. On the basis of product type, the market is divided into E1 and E2 enzymes as therapeutic targets, E3 enzymes as therapeutic targets, dub enzymes as therapeutic targets and associated drug class. On the basis of application, the Ubiquitin Enzymes Industry is divided into cancer, biological engineering and others.

Browse Research Report At: https://www.coherentmarketinsights.com/ongoing-insight/ubiquitin-enzymes-market-187

Increase in clinical trial success rate pushes pharmaceutical industries to invest more in ubiquitin enzyme studies

Regional segmentation of the ubiquitin enzymes market by Coherent Market Insights comprises North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America accounts for the largest share in the global ubiquitin enzymes market mainly due to increase in more number of research centers and presence of global pharma players which develop protein molecules for therapeutic activity process.

More than 40 clinical trial molecules in pipeline is expected to boost growth of Ubiquitin Enzymes Market

Key players operating the ubiquitin enzymes market include 3SBio, 5AM Ventures, Abbiotec, Abcam, AcelRx Pharmaceuticals, Aegera Therapeutics, Aeneas Ventures, Agilis Biotherapeutics,  Aileron Therapeutics, Alexion Pharmaceuticals and Amgen among others. Major market players are constantly working on research and development, as the market is largely untapped and offer highly lucrative growth opportunities. For instance, ubiquitin pathway based inhibitors, there are over 45 molecules that are under development which are used to treat a variety of indications. Considering the disturbingly high incidence rate of cancer across the globe, the ubiquitin enzymes market is expected to ride on a wave of positive growth in the foreseeable future.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Saturday 26 August 2017

Prefilled Syringes Market by Application, Material Type, and Design - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2016-2024

Highly consolidated market is expected to favor the sales revenue of prefilled syringes market:

There are around 20 pharmaceutical companies that are involved in manufacturing and marketing of prefilled syringes as preferred delivery device of around 50 injectable drugs and vaccines, which contributes significantly to the sales revenue of these players. Furthermore, there are few recent acquisitions by the big brands in market of prefilled syringes such as in 2012, Becton Dickinson and Company acquired Safety Syringes, Inc., which is further expected to favor the company’s syringes manufacturing efficiency and increase its product portfolio. Key players operating in the prefilled syringes market include Becton Dickinson & Co., Gerresheimer, Medtronic, Baxter International, SCHOTT AG, West Pharmaceuticals, Vetter International, Unilife Corporation, Stevanato Group, and Terumo Corporation

Request Sample Copy of the Business Report: https://www.coherentmarketinsights.com/insight/request-sample/162

Parenteral drugs are the second most preferred type of drugs after oral solid dosage forms and also holds second largest market share in terms of revenue in overall pharmaceutical market. Various benefits such as ease in administration, better patient compliance and 100% bioavailability are the few important factors that are expected to favor growth of the prefilled syringes market over the forecast period (2016–2024). Prefilled syringes segment is the one of the most important of the parenteral products market. However, volume sales in the market is rather low as it is a fairly novel product. The market is expected to gain traction over the forecast period, with increasing number of products and growing awareness among the populace about the benefits of the product.  There are various factors such as ease in administration and minimum contact with the exposed environment that are expected to favor growth of the prefilled syringes market in the near future. Use of syringes with prefilled drugs would be especially useful in emergency situations. According to Drug Development & Delivery, around 3.5 billion of prefilled syringes are produced each year and the existing numbers are expected to grow by the rate of around 9.0 – 10% annually.

Rising demand for biologics and self-injection products to augment market growth

A large number of newly approved biologics and drugs demand for PFS delivery devices for the subcutaneous (SC) self-injection of biopharmaceuticals. Also, the need for simpler self-injection procedures and improved patient compliance for auto injectors, large-volume patch injectors and pens is on the rise. This in turn is expected to favor growth of the prefilled syringes market over the forecast period (2016–2024). Patient exposure towards the routine injection can affect patient compliance, as it can cause significant discomfort to the user. Introduction of large volume biologics though, have helped rise in adoption rate of prefilled syringes. This in turn is expected to favor the market over the forecast period. Some factors such as growth in adoption of injectable drugs, success and growth of biologics, increased global vaccination, increased drug self-administration trend, technological advancements in the manufacture of PFS, and development of advanced PFS would further augment market growth.

Rise in number of applications is to favor the expansion of global prefilled syringes market:

Prefilled syringes market is expanding rapidly globally due to its various applications in overall healthcare sector. Nowadays, PFS manufacturing companies are focused on promoting use of the product in various application especially in homecare settings, which further is projected to favor increase in customer base in various regions. Furthermore, manufacturers are working towards developing PFS vaccines to help in indications such as various infectious disease and cancer. PFS are also being efficiently used in emergency medical services and in emergency section of hospitals. According to Frederick Furness Publishing Ltd, around 70% of atropine syringes prepared by the hospital staff are pre-filled and can be immediately used in emergency conditions.

Browse Global Strategic Business Report: https://www.coherentmarketinsights.com/ongoing-insight/prefilled-syringes-market-162

Prefilled Syringes market taxonomy:

By Application
  • Monoclonal Antibodies
  • Vaccines
  • Others
By Material Type
  • Polymer
  • PVC
  • Cyclo-olefin Polymer(COP)
  • Glass
By Design
  • Single Chambered
  • Dual Chambered
  • Multi-Chambered
About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Wednesday 23 August 2017

Pharmacy Benefit Management Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2024

Pharmaceutical drug prices continue soaring up and contribute significantly to total healthcare expenditure worldwide. The cost of drugs has risen more than any of the healthcare expenditure. As per the insurance consultants at Milliman, drug costs were merely 16% of the overall health costs in 2015, which rose by 102% over a decade and accounted for around 14% in 2015. Rising drug prices and increasing consumer spending on prescription drugs drives demand for pharmacy benefit managers (PBMs). The pharmacy benefit management system is operated by third party administrators (TPAs) who act as a liaison between pharmacists, insurance providers (payers), and drug manufacturers. There are established companies offering these services who aid in reducing drug prices by negotiating with retail pharmacies and drug manufacturers. Patients who have enrolled in various health plans and those uninsured can get the benefits of pharmacy benefit management system. Health plans collaborate with the pharmacy benefit managers to offer medications at a lower price than those available at retail pharmacies.

Request Sample Copy of the Business Report: https://www.coherentmarketinsights.com/insight/request-sample/62

Moreover, PBMs also aid in planning and managing the formulary as per customer needs, negotiating discounts and rebates with drug manufacturers, contracting with pharmacies, and processing the prescription claims. To manage the cost of prescription drugs and improve the customer value, PBMs use various tools such as pharmacy networks, mail-service pharmacies, drug formulary, e-prescribing, manufacturer’s discount, disease management, drug utilization review, and pharmacy discount cards (for the uninsured). To manage these tools and the PBMs account, there are various prescription claim software/systems marketed worldwide.

Pharmacy Benefit Management Market Taxonomy

The global pharmacy benefit management market can be analyzed on the basis of the beneficiaries of these services i.e. the healthcare providers, employers, and drug manufacturers. A major population in the U.S. receives healthcare benefits from their employers. Therefore, employers are also seeking to reduce their costs and opt for pharmacy benefit management services. The providers of pharmacy benefit management services also manage the prescription drug claims i.e. act as a link between the payers and health insurers.

The Pharmacy Benefit Management Market is Highly Concentrated in Developed Markets

The global market in pharmacy benefit management is analyzed across five major regions - North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. Presence of PBM is concentrated in the developed economies of North America and Europe. Increase in subscribers of Medicare prescription drug program is projected to fuel demand for PBMs in the U.S. Besides, the pharmacy benefit managers also aid in deciding whether a generic or branded product would benefit the patient. Patents for around 40 blockbuster brands worth US$ 155 billion are expected to expire by 2020. Generics have a good profit margin, which can benefit the pharmacy benefit managers/management companies, thus favorably shaping the pharmacy benefit management market outlook. Similar scenario is observed in the Europe pharmacy benefit management industry.

Browse Research Report At: https://www.coherentmarketinsights.com/ongoing-insight/pharmacy-benefit-management-market-62

Challenges faced in the Pharmacy Benefit Management Market

With the introduction of expensive treatments/drugs for chronic diseases such as cancer, and hepatitis, demand for PBMs is projected to increase significantly. However, even with the presence of major players in this industry, the PBMs have been ineffective in curbing the drug price hike. Further, with the advent of Affordable Care Act and the constant endeavor of governments to reduce and cap the drug prices, profitability of this industry is expected to be significantly impacted in the near future.

Some of the major players present in the global pharmacy benefit management market include Express Scripts, CVS Caremark, Prime Therapeutics, United Health / OptumRx, Catamaran Corporation, Humana Pharmacy Solutions and MedImpact. Express Scripts acquired Medco Health Solutions for US$ 29.1 billion in April 2012, making it a leader with a significant share in the global pharmacy benefit management industry. With increasing competition, industry consolidation is expected to be a prevalent trend in the near future.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Antacid Medications Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2024

Antacid Medications Market Overview

Antacids are used to treat acid reflux that causes heartburn, indigestion, and stomach upset. They provide quick relief from heartburn, which is a major symptom of gastroesophageal reflux disease and indigestion. Treatment with antacids is symptomatic and is usually recommended for minor symptoms. Antacids include magnesium carbonate, aluminum hydroxide, and magnesium trisilicate. Some people have reported allergic reactions to antacids. Antacids with magnesium may cause diarrhea, while those containing calcium and aluminum may cause constipation. Long-term use may cause kidney stones and may increase the risk of contracting osteoporosis. Popular antacid brands include Alka seltzer, Gelusil, Milk of Magnesia, Maalox, Gaviscon, Mylanta, Rolaids, and Tums.

Request Sample Copy of the Business Report: https://www.coherentmarketinsights.com/insight/request-sample/91

Distribution channel of Antacids

Antacids are mainly sold through two distribution channels, namely chemists and non-chemist. Non-chemists comprise grocers, general stores, and food stores. Abbott’s Digene and Pfizer’s Gelusil have a doctor heritage. Eno and Pudin Hara have an ayurvedic base and are available over the counter and are aiding in growth of the antacid medications market.  Over-the-counter availability of antacids have enabled individuals to self-medicate their bouts of acid reflux, which can increase probability of suffering from stroke in the future. Antacids are available in different forms such as water dissolving tablet, powder form, and melt-in-mouth granules.

Antacid medications market taxonomy – Formulation, Drug and Demographic

Antacid medications market is classified by various ways such as by formulation, drug and Demographic. On the basis of formulation, the antacid medications market is classified as tablets, capsules, suspensions, and drops. On the basis of demographic, antacid medications market is classified as products for pediatrics and products for adults. On the basis of drug, antacid medications market is classified as histamine-2 (H2) blockers, proton pump inhibitor, and pro-motility agents. Examples of H2 blocker include Nizatidine, Ranitidine, Cimetidine, and famotidine. Proton pump inhibitors used for acid reflux include Rabeprazole, Esomeprazole, Lansoprazole, Pantoprazole, and Omeprazole. Pro-motility agents stimulate the muscles of gastrointestinal tract and strengthen lower esophageal sphincter, and reduce reflux into esophagus. Metoclopramide is used to treat heartburn associated with GERD.

Increasing incidence of acid reflux in North America fueling growth of the antacid medications market

Increasing trend of self-medication consequently fuels demand for OTC digestive products for treatment of gastrointestinal distress. Antacids are used to neutralize acidity and thus, are expected to lead to rampant increase in demand for the same in North America due to rising incidence of gastroesophageal reflux disease (GERD) in the region. According to a study conducted by American Gastroenterological Association and published in International Foundation for Functional in February 2016, approximately one-third of the population in U.S. suffers from GERD. According to a study published in National Center for Biotechnology Information (NCBI) in June 2014, the range of GERD prevalence was 18.1%–27.8% in North America, 8.7%–33.1% in the Middle East, 8.8%–25.9% in Europe, 2.5%–7.8% in East Asia, and 11.6% in Australia. Increasing prevalence of GERD creates a favorable environment growth of the antacid medications market.

Browse Research Report At: https://www.coherentmarketinsights.com/ongoing-insight/antacid-medications-market-91

Increasing self-medication trend driving antacid medications market growth

Increasing inclination of the populace towards self-medication supplemented by growing availability of over-the-counter products in convenient to use sachets is a prevalent trend observed in the market. This trend is expected to continue over the forecast period, in turn fueling market growth.

Global players operating in the antacid medications market

Various companies manufacture antacids and other products for indigestion. Some of these are GlaxoSmithKline plc, Dabur India Limited, Abbott Laboratories, and Pfizer, Inc. Sun Pharma launched an ayurvedic digestive remedy called Pepmelt to compete with popular antacids such as Eno (GSK consumer healthcare), Digene (Abbott India), Pudin Hara (Dabur), and Gelusil (Pfizer). According to 2014 estimates of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), approximately 20% of the U.S. population suffered from gastroesophageal reflux disease, or GERD.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Antibacterial Drugs Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2024

Prevalence of bacterial infections and diseases is especially high in third world countries and significantly hampers quality of life across the globe. Further adding to the woes of the affected population is the increasing strains of bacteria that are resistant to conventional antibacterial drugs.  The epidemic of antibacterial resistance has spurred interest among the global healthcare organizations and a few pharmaceutical companies and research institutes to develop next-generation antibacterial drugs to effectively thwart such maladies. Unregulated and over prescription of antibacterial drugs has led to increased drug resistance. Moreover, genetic mutations are considered to be another major reason for antibacterial drug resistance. Ironically, these factors have greatly constrained the growth of antibacterial drugs market for years.

Request Sample Copy of the Business Report: https://www.coherentmarketinsights.com/insight/request-sample/177

Invention of Penicillin was a major breakthrough for treating bacterial infections. This stimulated research for more antibacterial drugs to treat different bacteria such as Escherichia coli, Klebsiella pneumonia, Staphylococcus aureus (MRSA) and Enterococcus species. However, price control and decreasing financial incentives discouraged pharmaceutical companies to conduct further research in this field. This has limited treatment options for bacterial infections, while discovery of new strains of infectious bacteria is on rise. Below is the timeline of antibacterial drug discovery:
The timeline highlights the large void in introduction of new antibacterial drugs during period 1960–2000. Streptomycin, sulfonamide, macrolide, nalidixic acid, aminoglycoside, tetracycline, and linezolid are among the bacterial resistant drugs.

Prospective drug candidates in research to improve the future outlook of the global antibacterial drugs market

The global antibacterial drugs market potential is estimated based on the current antibacterial drug classes, including those mentioned above and those in clinical trials. As of March 2016, there are around 37 drugs in clinical development for treating serious bacterial infections. These drugs are intended to be primarily launched in the U.S.
Moreover, FDA is encouraging development of new antibacterial drugs by laying out guidelines for the industry on the types of clinical studies to be conducted on antibacterial drug evaluation. This factor coupled with various incentives for research companies would create a positive outlook for the global antibacterial drugs resistance market in the near future.

Also, in March 2017, the WHO released a list of pathogens, classified based on the criticality/urgency, for which newer antibacterial drugs are required. The different environmental forces working towards development of newer antibacterial drugs would be a major continuing factor for the global antibacterial drugs market growth.

Alarming rise in drug resistant strains of bacteria driving awareness initiatives and programs by global healthcare organizations to back companies in the antibacterial drugs market

According to the Centers for Drug Disease Prevention and Control (CDC), every year at least 2 million people in the U.S. acquire bacterial infections that are resistant to drugs. Antibacterial resistance results in 23,000 deaths every year in the U.S. Moreover, according to the European Antimicrobial Resistance Surveillance Network (EARS-Net) data of November 2016, antibiotic resistance is higher in southern and south-eastern Europe than in northern Europe.

Browse Research Report At: https://www.coherentmarketinsights.com/ongoing-insight/antibacterial-drugs-market-177

Multiple drug resistance, as in case of tuberculosis, has further aggravated the treatment for specific conditions. According to the World health Organization (WHO), India has the highest burden of TB worldwide. Furthermore, the MDR-TB cases resistant to second-line drugs was 16% among already treated cases reported in 2015. Globally, an estimated 480,000 people developed MDR-TB in 2015 (WHO). The Government of India has drafted a national Strategic Plan 2017-2025 for eradicating TB in India. This would further propel the antibacterial drugs market in India.

The WHO has carved a ‘Global Action Plan on Antimicrobial Resistance’ in 2015 to fight against growing antibacterial resistance. CDC is also working in close collaboration with healthcare providers, pharmaceuticals companies, farmers, agriculture and environmental specialists, and representatives from Federal agencies to monitor, and control the prescription and use of antibacterial drugs. Such initiatives are expected to hold drugs for the future generation until the new drug launch and thus drive the antibacterial drugs market.

Some of the major players in the global antibacterial drugs market are Pfizer, Inc., Johnson & Johnson, AstraZeneca plc, F. Hoffmann-La Roche AG, Merck & Co., Inc., Evotec Pharmaceuticals, Allecra Therapeutics, Kyorin Pharmaceutical, and Allergan plc.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Tuesday 22 August 2017

Healthcare Revenue Cycle Management Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2024

Revenue cycle management or RCM is a combination of revenue generation, payment, and claims processing. In layman’s terms, it is a healthcare system’s financial system. Its components include all clinical and administrative functions that consist of the management, collection, and capture of revenue gained from patient service. It is primarily the entire lifespan of a patient account in a healthcare organization. Revenue cycle management incorporates the use of specific technological tools to track claims throughout patient’s lifecycle, ensuring that the payments are collected without any hurdle, and claims are addressed successfully. RCM tools let healthcare providers do the billing and identify issues quickly, thereby allowing for the secure stream of revenue. A system that runs efficiently thwarts rejection of claims and preserves an efficient and transparent billing process. Revenue cycle management also includes everything from deciding on patient’s insurance adequacy and eligibility to regulating claims through ICD-10.

Request Sample Copy of the Business Report: https://www.coherentmarketinsights.com/insight/request-sample/157

HRCM or healthcare revenue cycle management is an important architecture in a healthcare infrastructure. Healthcare organizations employ EHR or Electronic Health Records and computerized performance management to save costs related to the maintenance of their books. This is achieved by lessening the total number of claims denied and by facilitating individuals for adopting online payment platforms. The advent of superior automated elucidations has assisted front desk and clinical staffs, coders & billers, and providers to boost their performance levels in addition to saving time. With the growing business, patients are adopting more than a few payment gateways to make their payments against the services received at hospitals or clinics. Multiple advantages will propel the growth of healthcare revenue cycle management market in the near future.

Integrated solutions is likely to be the primary growth segment in the healthcare revenue cycle management market owing to improved operational competences and smooth economic and clinical structure with better management of treatments, outcomes and most importantly, costs related to these treatments.

Healthcare Revenue Cycle Management Market Taxonomy

On the basis of deployment, the global healthcare RCM market is classified into:
  • On-Premise
  • Cloud-Based
  • Web-Based
  • Others
On the basis of component, the global healthcare RCM market is classified into:
  • Software
  • Services
On the basis of product type, the global healthcare RCM market is classified into:
  • Standalone
  • Integrated
  • Others
On the basis of end user, the global healthcare RCM market is classified into:
  • Hospitals
  • Laboratories
  • Physicians
  • Others
Among deployment types, the cloud based solutions holds the majority share in the healthcare revenue cycle management market. The primary factor for the dominance of this segment is high rate of adoption of electronic medium for maintaining health records, thereby ensuring well-organized data mining, superior accessibility of the data and precise evaluation of the data corresponding to health information. This in turn will fuel the growth of the overall healthcare revenue cycle management market.

Browse Research Report At: https://www.coherentmarketinsights.com/ongoing-insight/healthcare-revenue-cycle-management-market-157

Rising incidences of hospitalizations will drive the overall healthcare revenue cycle management market

According to the American Hospital Association, the total number of registered hospitals in the U.S. was 5,564 in 2015. Moreover, it states that in 2015, the total number of admissions in these hospitals was 35,061,292, i.e. around 35 million patients. Increasing number of hospitalizations, in turn fuels growth of the global healthcare revenue cycle management systems market. Maintaining well organized records of patients is the need of the hour. Additionally, the emerging economies, especially countries such as China and India are likely to show significant growth prospects over the course of the forecast period. Increasing spends on healthcare, availability and accessibility of better healthcare facilities, increasing incidence of diseases and the rising importance of studying historical patient profile across the healthcare industry will augment the overall growth of the market. Government initiates and strict regulatory framework will shape the future of the global healthcare revenue cycle management market.

Major manufacturers in the market compete on the basis of price, and technology (ease of use). Some of the major players operating in the healthcare revenue cycle management market are GE Healthcare, Experian PLC., Eclinicalworks, LLC, Mckesson Corporation, Cerner Corporation, Gebbs Healthcare Solutions, Conifer Health Solutions, LLC. Epic Systems Corporation, Quest Diagnostics Incorporated, Allscripts Healthcare Solutions, Inc., and Athenahealth, Inc.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Monday 21 August 2017

Electronic Medical Records Market Size to Reach Close to US$ 40 Billion by 2024

The Global Electronic Medical Records Market was valued at US$ 21,444.4 million in 2015 and is projected to expand at a CAGR of 6.9% during the forecast period (2016–2024), as highlighted in a new report published by Coherent Market Insights. Increasing digitization is propelling deployment of EMR across the global healthcare sector.

Healthcare delivery is expected to undergo a drastic transformation through integration of information technology and healthcare services. The market is presenting new growth avenues for healthcare companies as well as major IT companies such as Apple and Microsoft. These companies are working in close coordination with healthcare service providers, understanding the various nitty-gritties of processes and problems and accordingly developing integrated solutions. Besides, emergence of health monitoring devices and applications and rising awareness among the populace about the ease of use and various benefits of such services led to increases demand for digital solutions to track health parameters and securely access personal medical records. Moreover, the advent of on-cloud EMR solutions further provides significant growth traction for the electronic medical records market.

Request Sample Copy of the Business Report: https://www.coherentmarketinsights.com/insight/request-sample/196

There are plethora of electronic medical record solutions available in the market, which makes the market highly competitive diverse scale of operations and unique requirements of users. However, the market provides highly lucrative growth opportunities, given the increasing inclination of various governments towards encouraging deployment of EMR in hospitals and private clinics. For instance, the Dubai government, has installed EMR system, Salama, across the Dubai Health Authority (DHA) network of health facilities. The government will be rolling out its MER system across the DHA network in three phases through 2017.

Furthermore, facilities already using EMR systems are upgrading to improve healthcare delivery. Catholic Health Services (CHS) and University of Maryland Medical System (UMMS) achieved Stage 6 recognition (almost fully automated/paperless medical records) by the Healthcare Information and Management Systems Society (HIMSS) Analytics on their Outpatient EMR adoption model of HIMSS Analytics. Deployment of new EMR systems and upgrading of systems would be significantly contributing towards growth of the global electronic medical records market.

At the same time, industry experts opine to have a defined legal framework for EMRs to avoid unnecessary legal issues. Emerging economies such as India, Brazil, Turkey, China, and Indonesia need to devise a framework for the use of EMR systems in their respective countries. In India, there are no defined legal framework in place to govern EMR and EHR systems, with preexisting IT laws applied to these systems. Cyber Laws, Indian Information Technology Act laws and compliances concerning health and medical industry are various governing laws posing a major challenge to smooth operations of present EMR systems. Healthcare facilities in India, using EMR systems, are facing challenges in complying with these laws and thus, are at risk of being faced with legal issues. Having a proper legal framework is essential in the growth path of electronic medical records market.

To know the latest trends and insights prevalent in the electronic medical records market, click the link below: https://www.coherentmarketinsights.com/market-insight/electronic-medical-records-market-196

Key takeaways of the market:
  • The global electronic medical records market is expected to expand at a CAGR of 6.9% during the forecast period (2016–2024) as there exists a huge demand especially in Asia Pacific, Latin America, Middle East and Africa markets
  • Cloud-based solutions are expected to fuel the global electronic medical records market growth exponentially during the forecast period. Chain of hospitals and diagnostic laboratories who can afford cloud-based EMR systems find it very beneficial for their patients.
  • Hospitals are the major end users of EMR systems as these organizations deal with a huge patient database and have high demand among their patients to access their medical records
  • The demand for EMR is growing in ambulatory/outpatient services, which is expected to fuel the growth of this market in near future
  • High healthcare spending and rapid digitization has supported the North America and European regions to dominate this market. However, increasing funding in emerging regions driving better healthcare infrastructure would drive substantial demand in Asia Pacific and Latin America during the forecast period.
  • Some of the major players involved in global electronic medical records market include Cerner Corporation, Allscripts-Misys Healthcare Solutions Inc., McKesson Corporation, Quadramed Corporation, Medical Information Technology Inc., Sage Software Healthcare Inc., Greenway Health, LLC, NextGen Healthcare Information Systems, LLC, Epic Systems Corporation, and GE Healthcare.
About CMI

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.